Develops and manufactures prescription and over-the-counter (OTC) medications. Produces hydrocarbon aerosols for dermatological and topical drug delivery. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 1,988% a year over the last 3 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 1,988% a year on average.
Sales run at $495.6M a year. A small number, but proof the product has real buyers.
A loss of $31.0M against $495.6M in annual sales.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.